Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells - PubMed (original) (raw)
. 2009 Nov 1;284(2):141-8.
doi: 10.1016/j.canlet.2009.04.026. Epub 2009 May 17.
Affiliations
- PMID: 19447545
- DOI: 10.1016/j.canlet.2009.04.026
Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells
Lin Chen et al. Cancer Lett. 2009.
Abstract
Chimeric adenoviral vectors possessing fiber derived from human adenovirus subgroup B (Ad35) have been developed for their high infection efficiency in cell types which are refractory to adenovirus serotype 5 (Subgroup C). The present study constructed an E1B-deleted chimeric oncolytic adenovirus, SG235-TRAIL, which carries a human TRAIL gene expression cassette and whose fiber shaft and knob domains are from serotype Ad35. It was found that SG235-TRAIL preferentially replicated in gastric cancer cell lines, SGC-7901 and BGC-823 compared to in normal human fibroblast BJ cells. Also, when compared with a replication-deficient chimeric vector Ad5/35-TRAIL, SG235-TRAIL mediated a higher level of the transgene expression via viral replication in the cancer cells. Further, because of the more efficient cell-entry and infection, SG235-TRAIL induced stronger cell apoptosis than the Ad5 CRAD vector, ZD55-TRAIL. In addition, SG235-TRAIL in combination with the chemotherapeutic drug, taxol, produced a synergistic cytotoxic effect in cancer cells in vitro without causing significant toxicity to normal cells. In the gastric tumor xenograft mouse model, intratumoral SG235-TRAIL injection produced a significant antitumor effect 14 days after treatment. Pathological examination demonstrated TRAIL expression and associated apoptosis in majority of SG235-TRAIL-treated tumor cells. These results suggest that SG235-TRAIL is a potential novel, efficient anti-cancer agent, and in combination with taxol, it would be even more useful with considerably low toxic side effects.
2009 Elsevier Ireland Ltd.
Similar articles
- E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.
Wang G, Li G, Liu H, Yang C, Yang X, Jin J, Liu X, Qian Q, Qian W. Wang G, et al. J Gene Med. 2009 Jun;11(6):477-85. doi: 10.1002/jgm.1326. J Gene Med. 2009. PMID: 19340843 - A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME, Beard BC, Lieber A, Kiem HP. Wohlfahrt ME, et al. Cancer Res. 2007 Sep 15;67(18):8783-90. doi: 10.1158/0008-5472.CAN-07-0357. Cancer Res. 2007. PMID: 17875719 - The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.
Zhao L, Dong A, Gu J, Liu Z, Zhang Y, Zhang W, Wang Y, He L, Qian C, Qian Q, Liu X. Zhao L, et al. Cancer Gene Ther. 2006 Nov;13(11):1011-22. doi: 10.1038/sj.cgt.7700969. Epub 2006 Jun 23. Cancer Gene Ther. 2006. PMID: 16799468 - Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Horowitz J. Horowitz J. Curr Opin Mol Ther. 1999 Aug;1(4):500-9. Curr Opin Mol Ther. 1999. PMID: 11713766 Review. - TRAIL as a target in anti-cancer therapy.
Wu GS. Wu GS. Cancer Lett. 2009 Nov 18;285(1):1-5. doi: 10.1016/j.canlet.2009.02.029. Epub 2009 Mar 18. Cancer Lett. 2009. PMID: 19299078 Review.
Cited by
- Oncolytic virus: A catalyst for the treatment of gastric cancer.
Wang J, Du L, Chen X. Wang J, et al. Front Oncol. 2022 Nov 24;12:1017692. doi: 10.3389/fonc.2022.1017692. eCollection 2022. Front Oncol. 2022. PMID: 36505792 Free PMC article. Review. - Oncolytic virotherapy in upper gastrointestinal tract cancers.
Yokoda R, Nagalo BM, Arora M, Egan JB, Bogenberger JM, DeLeon TT, Zhou Y, Ahn DH, Borad MJ. Yokoda R, et al. Oncolytic Virother. 2018 Mar 23;7:13-24. doi: 10.2147/OV.S161397. eCollection 2017. Oncolytic Virother. 2018. PMID: 29616200 Free PMC article. Review. - Tumor necrosis factor-related apoptosis inducing ligand overexpression and Taxol treatment suppresses the growth of cervical cancer cells in vitro and in vivo.
Sun X, Cui M, Wang D, Guo B, Zhang L. Sun X, et al. Oncol Lett. 2018 Apr;15(4):5744-5750. doi: 10.3892/ol.2018.8071. Epub 2018 Feb 16. Oncol Lett. 2018. PMID: 29556305 Free PMC article. - C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy.
Klein SR, Piya S, Lu Z, Xia Y, Alonso MM, White EJ, Wei J, Gomez-Manzano C, Jiang H, Fueyo J. Klein SR, et al. Oncogene. 2015 Oct 8;34(41):5295-301. doi: 10.1038/onc.2014.452. Epub 2015 Jan 26. Oncogene. 2015. PMID: 25619840 Free PMC article. - Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.
Bauzon M, Hermiston T. Bauzon M, et al. Front Immunol. 2014 Feb 24;5:74. doi: 10.3389/fimmu.2014.00074. eCollection 2014. Front Immunol. 2014. PMID: 24605114 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical